Tharimmune Inc (THAR)

$1.80 +0.04 (2.41%)
Market Cap 4.80M
Revenue (ttm) 0.00
Net Income (ttm) -12.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.31
Volume 41,400
Avg Vol 101,516
Day's Range N/A - N/A
Shares Out 2.66M
Stochastic %K 92%
Beta 1.04
Analysts Strong Sell
Price Target $17.00

Company Profile

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets prog...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 270 8260
Address:
1200 Route 22 East, Suite 2000, Bridgewater, United States
tusambolo
tusambolo Jun. 26 at 3:54 PM
$THAR insiders buying for a $CYN run.
0 · Reply
gemini112
gemini112 Jun. 24 at 8:43 PM
$THAR Is the recent resignation of board members an indication of a possible buyout? Im a new here and dont know much about companies history. .
0 · Reply
TruthTooPower
TruthTooPower Jun. 24 at 5:29 PM
$THAR !!! Are You Ready to Rock??? $INDP $IPA
0 · Reply
Dingo2
Dingo2 Jun. 24 at 5:16 PM
$THAR this low floater is overdue for a skyward pop :)
0 · Reply
gemini112
gemini112 Jun. 24 at 3:16 PM
$THAR 65 day average day volume is 125k. this is a stock that moves slowly. All you need is patience.
0 · Reply
tusambolo
tusambolo Jun. 24 at 2:30 PM
$THAR I guess half million dollars buy is not enough.
0 · Reply
StockElementCorporation
StockElementCorporation Jun. 24 at 12:48 PM
📓 Top Insider Buys $RZLT – 1.23M shares ($4.0M) $PLTR – 1.04M shares ($2.15M) $THAR – 337.8K shares ($500K) $THO – 3K shares ($256.2K) $ORIC – 26.6K shares ($249.7K) MBRX – 675.7K shares ($250K) MBRX – 270.3K shares ($100K)
0 · Reply
MGeronimo
MGeronimo Jun. 24 at 12:19 PM
$THAR IN AT 1.31 on huge insider buying
0 · Reply
AlertsAndNews
AlertsAndNews Jun. 24 at 2:59 AM
$THAR Insider Buy here Gravitas Capital LP (Director, Executive Chairman, 10%+) Buys 337,838 shares @ $1.48 avg.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jun. 24 at 1:35 AM
$THAR CEO purchased 61,496 shares at $1.48 for a total of $90,973. Appajosyula Sireesh now owns 64,868 shares. https://ceo-buys.com
0 · Reply
Latest News on THAR
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Jun 17, 2025, 8:01 AM EDT - 13 days ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025, 8:01 AM EDT - 7 weeks ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025, 8:01 AM EDT - 2 months ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 30, 2025, 8:01 AM EDT - 2 months ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 28, 2025, 8:01 AM EDT - 2 months ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 2 months ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Apr 7, 2025, 8:00 AM EDT - 3 months ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 24, 2025, 8:00 AM EDT - 3 months ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Mar 4, 2025, 7:00 AM EST - 4 months ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Tharimmune to Present at the Microcap Conference 2025

Jan 27, 2025, 8:30 AM EST - 5 months ago

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 16, 2024, 8:00 AM EST - 7 months ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Dec 6, 2024, 4:15 PM EST - 7 months ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 18, 2024, 8:00 AM EST - 8 months ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 13, 2024, 8:00 AM EST - 8 months ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Nov 4, 2024, 9:00 AM EST - 8 months ago

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 30, 2024, 8:00 AM EDT - 8 months ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Oct 28, 2024, 9:00 AM EDT - 8 months ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 30, 2024, 7:00 AM EDT - 9 months ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Sep 16, 2024, 7:00 AM EDT - 10 months ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 30, 2024, 8:31 AM EDT - 1 year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 23, 2024, 7:31 AM EDT - 1 year ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Mar 5, 2024, 8:31 AM EST - 1 year ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 20, 2024, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Feb 5, 2024, 8:30 AM EST - 1 year ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Jan 29, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Dec 11, 2023, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Nov 30, 2023, 4:01 PM EST - 1 year ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Nov 27, 2023, 9:40 PM EST - 1 year ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Nov 27, 2023, 8:00 AM EST - 1 year ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Tharimmune Announces 1-for-25 Reverse Stock Split

Nov 17, 2023, 7:00 AM EST - 1 year ago

Tharimmune Announces 1-for-25 Reverse Stock Split

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Nov 6, 2023, 5:35 PM EST - 1 year ago

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Sep 22, 2023, 8:30 AM EDT - 1 year ago

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Sep 11, 2023, 11:51 AM EDT - 1 year ago

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Sep 8, 2023, 2:30 PM EDT - 1 year ago

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Aug 9, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Jul 10, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Jul 6, 2023, 8:30 AM EDT - 2 years ago

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

May 15, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

May 2, 2023, 4:05 PM EDT - 2 years ago

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

May 2, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

Hillstream BioPharma Announces Pricing of Public Offering

Apr 27, 2023, 9:50 PM EDT - 2 years ago

Hillstream BioPharma Announces Pricing of Public Offering

Hillstream BioPharma Announces Proposed Public Offering

Apr 27, 2023, 4:00 PM EDT - 2 years ago

Hillstream BioPharma Announces Proposed Public Offering

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

Apr 13, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow

Apr 12, 2023, 10:30 AM EDT - 2 years ago

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow

tusambolo
tusambolo Jun. 26 at 3:54 PM
$THAR insiders buying for a $CYN run.
0 · Reply
gemini112
gemini112 Jun. 24 at 8:43 PM
$THAR Is the recent resignation of board members an indication of a possible buyout? Im a new here and dont know much about companies history. .
0 · Reply
TruthTooPower
TruthTooPower Jun. 24 at 5:29 PM
$THAR !!! Are You Ready to Rock??? $INDP $IPA
0 · Reply
Dingo2
Dingo2 Jun. 24 at 5:16 PM
$THAR this low floater is overdue for a skyward pop :)
0 · Reply
gemini112
gemini112 Jun. 24 at 3:16 PM
$THAR 65 day average day volume is 125k. this is a stock that moves slowly. All you need is patience.
0 · Reply
tusambolo
tusambolo Jun. 24 at 2:30 PM
$THAR I guess half million dollars buy is not enough.
0 · Reply
StockElementCorporation
StockElementCorporation Jun. 24 at 12:48 PM
📓 Top Insider Buys $RZLT – 1.23M shares ($4.0M) $PLTR – 1.04M shares ($2.15M) $THAR – 337.8K shares ($500K) $THO – 3K shares ($256.2K) $ORIC – 26.6K shares ($249.7K) MBRX – 675.7K shares ($250K) MBRX – 270.3K shares ($100K)
0 · Reply
MGeronimo
MGeronimo Jun. 24 at 12:19 PM
$THAR IN AT 1.31 on huge insider buying
0 · Reply
AlertsAndNews
AlertsAndNews Jun. 24 at 2:59 AM
$THAR Insider Buy here Gravitas Capital LP (Director, Executive Chairman, 10%+) Buys 337,838 shares @ $1.48 avg.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jun. 24 at 1:35 AM
$THAR CEO purchased 61,496 shares at $1.48 for a total of $90,973. Appajosyula Sireesh now owns 64,868 shares. https://ceo-buys.com
0 · Reply
Social_Idiot
Social_Idiot Jun. 20 at 5:35 PM
$THAR Just came across this ticker. Whoa CFO abrupt exit.
2 · Reply
TwongStocks
TwongStocks Jun. 16 at 8:25 PM
$THAR CFO resigned effective immediately https://www.sec.gov/ix?doc=/Archives/edgar/data/1861657/000164117225015248/form8-k.htm
0 · Reply
FullportFox
FullportFox Jun. 15 at 7:07 PM
$THAR news is due
0 · Reply
tusambolo
tusambolo Jun. 12 at 2:51 PM
$THAR no pump before the dump? I guess we are heading for a r/s after they take it below a dollar.
0 · Reply
TwongStocks
TwongStocks Jun. 12 at 10:58 AM
$THAR Transformation complete. This is a completely different company than when it IPO'd three years ago. Different name and ticker. Different pipeline. And now, different CEO.
0 · Reply
TwongStocks
TwongStocks Jun. 11 at 9:42 PM
$THAR Randy Milby is out as CEO. New CEO is Sireesh Appajosyula . https://www.sec.gov/ix?doc=/Archives/edgar/data/0001861657/000164117225014753/form8-k.htm
0 · Reply
tusambolo
tusambolo Jun. 9 at 6:28 PM
$THAR ready to move north
0 · Reply
Dani_G_German
Dani_G_German Jun. 2 at 4:41 PM
$THAR anyone knows their cash position?
1 · Reply
tusambolo
tusambolo May. 12 at 2:26 PM
$THAR cup and handle
0 · Reply
tusambolo
tusambolo May. 10 at 7:44 PM
$THAR dilution is coming so let's get ready for a good pump and dump I am hoping for $3.
0 · Reply
FoxRunnerNews
FoxRunnerNews May. 6 at 1:05 PM
$THAR Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback https://foxrunner.com?fpr=newsscanner&fp_sid=trial
0 · Reply